Gemini Therapeutics (NASDAQ:GMTX – Get Rating) and Prestige Consumer Healthcare (NYSE:PBH – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Risk & Volatility

Gemini Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Institutional and Insider Ownership

83.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 99.4% of Prestige Consumer Healthcare shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

Prestige Consumer Healthcare has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Gemini Therapeutics and Prestige Consumer Healthcare, as reported by MarketBeat.com.

Gemini Therapeutics presently has a consensus target price of $6.90, suggesting a potential upside of 403.65%. Prestige Consumer Healthcare has a consensus target price of $80.50, suggesting a potential upside of 58.62%. Given Gemini Therapeutics' higher possible upside, equities research analysts plainly believe Gemini Therapeutics is more favorable than Prestige Consumer Healthcare.

Profitability

This table compares Gemini Therapeutics and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Summary

Prestige Consumer Healthcare beats Gemini Therapeutics on 10 of the 12 factors compared between the two stocks.

About Gemini Therapeutics

(Get Rating)

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

About Prestige Consumer Healthcare

(Get Rating)

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.